Search hospitals > Nevada > Las Vegas
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Claim this profileLas Vegas, Nevada 89128
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
140 reported clinical trials
1 medical researcher
Summary
HealthCare Partners Medical Group Oncology/Hematology-Tenaya is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. HealthCare Partners Medical Group Oncology/Hematology-Tenaya is involved with conducting 140 clinical trials across 326 conditions. There are 1 research doctors associated with this hospital, such as John A. Ellerton.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Clinical Trials running at HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Non-Small Cell Lung Cancer
Bladder Carcinoma
Lung Cancer
Breast Cancer
Bladder Cancer
Renal Cell Carcinoma
Cancer
Ovarian Tumors
Gastric Cancer
Esophageal Adenocarcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at HealthCare Partners Medical Group Oncology/Hematology-Tenaya?
HealthCare Partners Medical Group Oncology/Hematology-Tenaya is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. HealthCare Partners Medical Group Oncology/Hematology-Tenaya is involved with conducting 140 clinical trials across 326 conditions. There are 1 research doctors associated with this hospital, such as John A. Ellerton.